At a glance
- Originator PharmaMar
- Class Antineoplastics
- Mechanism of Action Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 20 Feb 1997 Preclinical development for Cancer in Spain (Unknown route)